TNR Biopharm's cumulative revenue reaches ₩27.2B in the third quarter
Predicted impact: Low
Cumulative Q3 revenue of ₩27.2B is about 83% of last year's; preliminary earnings already filed.
T&R Biofab티앤알바이오팹
246710 · KOSDAQ · ₩246710 · 티앤알바이오팹
₩1,940▼ ₩20 (1.02%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y +9.57%
- Market cap
- ₩92B
- Enterprise value
- ₩116B
- P/E
- —
- P/B
- 4.4×
- Dividend yield
- 0.0%
- ROE
- −130.7%
- Net margin
- −84.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−60.6% from the high
₩1,127Today: ₩1,911 – ₩1,999₩4,925
Returns
- 1W−4.0%
- 1M−15.3%
- 3M−17.6%
- 6M−36.8%
- YTD−50.4%
- 1Y+9.6%
- Volume today
- 77,924
- 0.6× the 20-day average
- Traded today
- ₩153M
- Listed shares
- 47,664,504
- EPS (12 months)
- −₩581
- Earnings yield −30.0%
AI research · InitiationT&R Biofab: Revenue Jumped in 2025 but Losses and Leverage Remain HeavyThe data shows a real jump in revenue and a narrower operating loss, but also deep net losses, a negative return on equity, high leverage and amended filings.Read the full report →
Upcoming dates
- Nov 16Earnings Expected · 3Q results
- Nov 16Earnings Expected · 3Q results
- Jan 21Earnings Expected · Preliminary results
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
- MomentumWeak-14.3% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
T&R Biofab stock overview
T&R Biofab (티앤알바이오팹, KRX: 246710) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and sells 3D bioprinting systems, bioinks made from tissue-specific extracellular matrix, and biodegradable scaffolds used in tissue regeneration. Its shares closed at ₩1,940 on Oct 27, 2026, down 1.02% on the day, giving it a market value of ₩92B.
Key facts
- Market cap
- ₩92B
- Sector
- Biotech & Pharma
- Latest price change
- −1.02%
- As of
- Oct 27, 2026
- Main business
- The company develops and sells 3D bioprinting systems, bioinks made from tissue-specific extracellular matrix, and biodegradable scaffolds used in tissue regeneration.
Quick answers about T&R Biofab
- What does T&R Biofab do?
- The company develops and sells 3D bioprinting systems, bioinks made from tissue-specific extracellular matrix, and biodegradable scaffolds used in tissue regeneration. Its business is organized into regenerative medicine, bio-surgical solutions, and cosmetics, and it is developing 3D organoids and 3D cell therapies. Its biodegradable scaffolds, such as the CFI and PSI implants, are used in craniofacial reconstruction and correction in Korea.
- What is the market cap of T&R Biofab?
- The market capitalisation of T&R Biofab was ₩92B at the close on Oct 27, 2026.
- Who are the largest shareholders of T&R Biofab?
- According to the latest official filings, the largest reported holders are Yoon Won-su (15.03%, as of Aug 19, 2026); Korea Investment Partners (4.75%, as of Nov 10, 2025); Sim Jin-hyeong (3.55%, as of Aug 4, 2026).
- When is the next earnings report from T&R Biofab?
- Korean companies rarely announce results dates in advance. Based on when T&R Biofab filed the same report in past years, its next 3q results is expected between Nov 14, 2026 and Dec 1, 2026.
- Does the National Pension Service own T&R Biofab?
- Yes. The National Pension Service held 0.95% of T&R Biofab shares as of Dec 31, 2023.
Company profile
The company develops and sells 3D bioprinting systems, bioinks made from tissue-specific extracellular matrix, and biodegradable scaffolds used in tissue regeneration. Its business is organized into regenerative medicine, bio-surgical solutions, and cosmetics, and it is developing 3D organoids and 3D cell therapies. Its biodegradable scaffolds, such as the CFI and PSI implants, are used in craniofacial reconstruction and correction in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 티앤알바이오팹
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 윤원수
- Founded
- Mar 2013
- Listed
- Nov 2018
- Listed shares
- 47,664,504
- Fiscal year ends
- Month 12
- Website
- www.tnrbiofab.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Preliminary earnings (consolidated)Oct 19, 2026
- Half-year report (Jun 2026)Aug 31, 2026
- Amended attachment: Annual report (Dec 2025)Aug 27, 2026
- [Amendment] Occurrence of Derivative Trading LossAug 25, 2026
- Amended: Audit report submittedAug 25, 2026
Titles in Korean until English translations are added.
Also known as: T&R Biofab / 티앤알바이오팹 / 246710 / KRX:246710
Source: KRX statistical information